OREANDA-NEWS. December 09, 2013. The Federal Antimonopoly Service (FAS Russia) initiated a case against “Baxter” CJSC upon failure to execute a warning issued by FAS that it would be unacceptable to refuse supplying a unique medicine for treating renal insufficiency by peritoneal dialysis.

“Baxter” CJSC refused to supply “Extranil” (the International Non-Proprietary Name –“Icodextrin”) to “Medical Service Company” Ltd. that offers integrated medical services for organizing and executing out-patient peritoneal dialysis in the Samara region.

Having analyzed the market of “Icodextrin”, FAS included “Baxter” CJSC in the Register of persons that have dominant position.

In the FAS opinion, the procedures used by “Baxter” CJSC to choose counteragents do not have a clear criteria for selecting and approving counteragents, the deadlines and the procedures for considering offers, the procedures and conditions for working with them, and terminating contractual relations, the criteria and deadlines for decision-making. The economically and technologically unjustified refusal by to supply the medicine has signs of violating Clause 5 Part 1 Article 10 of the Federal Law “On Protection of Competition” and leads to restricting competition and infringing the interests of “Medical Service Company” Ltd.